1. Atezolizumab was associated with non-significantly increased disease-free survival compared to placebo (57.2 months vs. 49.5 months). 2. Serious adverse ...
Click to read the study in The Lancet Oncology.
1. Median overall survival and progression-free survival were significantly improved with cemiplimab monotherapy compared to chemotherapy. 2. Patients treated with ...
2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.
